NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Daniel Carcillo Joins BetterLife Pharma as Corporate Advisor
TL;DR
BetterLife Pharma gains competitive advantage by hiring former NHL champion Daniel Carcillo to advance their non-hallucinogenic LSD derivative BETR-001 for traumatic brain injury treatment.
BetterLife's BETR-001 is a non-controlled LSD derivative in preclinical development that can be self-administered for neurological disorders with patent protection until approximately 2042.
This development offers hope for athletes, veterans, and concussion survivors to heal from traumatic brain injuries and regain their quality of life through accessible treatment.
A two-time Stanley Cup champion forced to retire from concussions now advises a biotech company developing a non-hallucinogenic LSD derivative to treat brain injuries.
Found this article helpful?
Share it with your network and spread the knowledge!
BetterLife Pharma has appointed Daniel Carcillo, former NHL hockey player and TBI advocate, as Corporate Advisor to help advance the development of BETR-001 for traumatic brain injury, cluster headache, and migraine treatment.
Daniel Carcillo is a Canadian former professional hockey player who won two Stanley Cups with the Chicago Blackhawks and was forced to retire due to Post Concussion Syndrome. He joins BetterLife to help advance BETR-001 development, drawing from his personal experience with brain trauma and his advocacy work for TBI survivors.
BETR-001 is BetterLife Pharma's proprietary non-hallucinogenic derivative of LSD that is in preclinical and IND-enabling studies for treating traumatic brain injury, cluster headache, and migraine. It is unique because it is unregulated and can be self-administered.
BETR-001 is unique because it is a non-hallucinogenic and non-controlled LSD derivative that is unregulated, eliminating regulatory hurdles and allowing for self-administration, while still providing serotonergic benefits for neurological disorders.
After retiring from the NHL in 2015 due to seven concussions and Post Concussion Syndrome, Carcillo created a non-profit organization to assist former NHL players with post-concussion syndrome and mental health issues, and was the founder and CEO of Wesana Health, a company using psilocybin-based medicine to treat traumatic brain injuries.
BetterLife has a synthesis patent for BETR-001 that eliminates regulatory hurdles, and a pending patent for composition and method of use that covers treatment of various neurological disorders until around 2042.
BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for its further development.
You can contact Ahmad Doroudian, Chief Executive Officer, at Ahmad.Doroudian@blifepharma.com or by phone at 1-604-221-0595. More information is also available at their website.
BETR-001 is currently in preclinical and IND-enabling studies, meaning it is in the early stages of development before human clinical trials.
Carcillo stated that joining BetterLife feels like the natural next step in his mission to help concussion survivors because they are advancing a medicine that offers psychedelic healing benefits without regulatory barriers, giving people with brain trauma a real chance to heal and get their lives back.
Curated from NewMediaWire
